Abstract
Background and Aims : Angiopoietin-like 3 (ANGPTL3) is an inhibitor of lipoprotein lipase (LPL) and endothelial lipase (EL). The impact of ANGPTL3 lowering has been shown to depend on the type of dyslipidemia: reduced LDL cholesterol in patients with familial hypercholesterolemia and reductions in plasma triglycerides in patients with chylomicronemia. This differential effect may be related to a difference in the association of ANGPTL3 with lipoproteins. We therefore hypothesized that ANGPTL3 resides on lipoproteins and that this affects its ability to suppress lipase activity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
